Literature DB >> 15864691

Surgical treatment of brain metastasis.

Takamitsu Fujimaki1.   

Abstract

Treatment modalities for brain metastasis or metastatic brain tumor include surgery, conventional irradiation, stereotactic radiosurgery (SRS), chemotherapy, and supportive care with corticosteroid. In most cases, these treatments are used in combination. For a single metastasis, surgery followed by whole-brain radiation therapy (WBRT) has been the standard treatment. SRS has become increasingly popular and challenges the standard procedure, but there are still insufficient data for the outcomes of combinations including SRS. For the treatment of multiple metastases, WBRT is the standard procedure. For tumors larger than 3 cm, and in life-threatening situations such as a large metastasis to the cerebellum, surgery is the only feasible approach. Histological examination is sometimes useful for characterizing metastatic tumors from unknown primary sites. Thus, although brain metastasis invariably indicates a stage 4 cancer, some patients can benefit from surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864691     DOI: 10.1007/s10147-005-0480-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  3 in total

1.  Mathematical model for the cancer stem cell hypothesis.

Authors:  R Ganguly; I K Puri
Journal:  Cell Prolif       Date:  2006-02       Impact factor: 6.831

2.  Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse.

Authors:  Davide Adriano Santeufemia; Gianfranca Piredda; Giovanni Maria Fadda; Paolo Cossu Rocca; Salvatore Costantino; Giovanni Sanna; Maria Giuseppa Sarobba; Maria Antonietta Pinna; Carlo Putzu; Antonio Farris
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

3.  Reduced glioma infiltration in Src-deficient mice.

Authors:  Caren V Lund; Mai T N Nguyen; Geoffrey C Owens; Andrew J Pakchoian; Ashkaun Shaterian; Carol A Kruse; Brian P Eliceiri
Journal:  J Neurooncol       Date:  2006-03-22       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.